COLL COLLEGIUM PHARMACEUTICAL INC revenue, earnings and financials

For the quarter ended June 30, 2026, COLLEGIUM PHARMACEUTICAL INC reported revenue of $200M (up 6.3% from a year earlier), net income of −$15.1M and diluted EPS of −$0.46; over the last four quarters revenue was $808M and net income $47.9M; for the fiscal year ended December 2025 revenue was $781M, up 23.6% on the year before.

COLL annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $781M, gross profit $463M, operating income $180M, net income $63.0M (margin 8.1%), EPS $1.73
• Fiscal year ended Dec 2024: revenue $631M, gross profit $377M, operating income $170M, net income $69.0M (margin 10.9%), EPS $1.86
• Fiscal year ended Dec 2023: revenue $567M, gross profit $326M, operating income $167M, net income $48.0M (margin 8.5%), EPS $1.29
• Fiscal year ended Dec 2022: revenue $464M, gross profit $209M, operating income $33.3M, net income −$25.0M (margin -5.4%), EPS −$0.74
• Fiscal year ended Dec 2021: revenue $277M, gross profit $151M, operating income $17.6M, net income $72.0M (margin 26.0%), EPS $1.86

COLL quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $200M (up 6.3% year over year), net income −$15.1M, EPS −$0.46
• Quarter ended Mar 31, 2026: revenue $194M (up 8.9% year over year), net income $14.5M, EPS $0.40
• Quarter ended Dec 31, 2025: revenue $205M (up 12.9% year over year), net income $17.0M, EPS $0.46
• Quarter ended Sep 30, 2025: revenue $209M (up 31.4% year over year), net income $31.5M, EPS $0.84
• Quarter ended Jun 30, 2025: revenue $188M (up 29.4% year over year), net income $12.0M, EPS $0.34
• Quarter ended Mar 31, 2025: revenue $178M (up 22.7% year over year), net income $2.42M, EPS $0.07
• Quarter ended Dec 31, 2024: revenue $182M (up 21.5% year over year), net income $12.5M, EPS $0.36
• Quarter ended Sep 30, 2024: revenue $159M (up 16.5% year over year), net income $9.34M, EPS $0.27
• Quarter ended Jun 30, 2024: revenue $145M (up 7.2% year over year), net income $19.6M, EPS $0.52
• Quarter ended Mar 31, 2024: revenue $145M (up 0.1% year over year), net income $27.7M, EPS $0.71
• Quarter ended Dec 31, 2023: revenue $150M (up 15.5% year over year), net income $31.9M, EPS $0.82
• Quarter ended Sep 30, 2023: revenue $137M (up 7.6% year over year), net income $20.6M, EPS $0.53
• Quarter ended Jun 30, 2023: revenue $136M (up 9.7% year over year), net income $13.0M, EPS $0.34
• Quarter ended Mar 31, 2023: revenue $145M (up 72.9% year over year), net income −$17.4M, EPS −$0.51
• Quarter ended Dec 31, 2022: revenue $130M (up 373.7% year over year), net income −$7.20M, EPS −$0.21
• Quarter ended Sep 30, 2022: revenue $127M (up 61.1% year over year), net income $457K, EPS $0.01
• Quarter ended Jun 30, 2022: revenue $124M (up 49.0% year over year), net income −$5.19M, EPS −$0.15
• Quarter ended Mar 31, 2022: revenue $83.8M (down 4.5% year over year), net income −$13.1M, EPS −$0.39
• Quarter ended Dec 31, 2021: revenue $27.4M, net income −$25.0M, EPS −$0.73
• Quarter ended Sep 30, 2021: revenue $78.8M, net income $8.05M, EPS $0.22

COLL cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $329M, share buybacks $25.1M
• Fiscal year ended Dec 2024: operating cash flow $205M, share buybacks $60.0M
• Fiscal year ended Dec 2023: operating cash flow $275M, share buybacks $75.0M
• Fiscal year ended Dec 2022: operating cash flow $124M, share buybacks $14.1M
• Fiscal year ended Dec 2021: operating cash flow $104M, share buybacks $47.9M

COLL balance sheet

• Jun 30, 2026: cash $129M, total assets $2.14B, total liabilities $1.82B, shareholders' equity $312M
• Mar 31, 2026: cash $269M, total assets $1.65B, total liabilities $1.34B, shareholders' equity $312M
• Dec 31, 2025: cash $231M, total assets $1.66B, total liabilities $1.36B, shareholders' equity $302M
• Sep 30, 2025: cash $150M, total assets $1.61B, total liabilities $1.33B, shareholders' equity $275M
• Jun 30, 2025: cash $117M, total assets $1.59B, total liabilities $1.36B, shareholders' equity $232M
• Mar 31, 2025: cash $96.2M, total assets $1.63B, total liabilities $1.40B, shareholders' equity $234M
• Dec 31, 2024: cash $70.6M, total assets $1.66B, total liabilities $1.43B, shareholders' equity $229M
• Sep 30, 2024: cash $39.0M, total assets $1.64B, total liabilities $1.40B, shareholders' equity $234M

What is COLL's revenue?

COLLEGIUM PHARMACEUTICAL INC reported $808M of revenue over its last four quarters, through June 30, 2026.

Is COLL profitable?

Yes. COLLEGIUM PHARMACEUTICAL INC earned $47.9M over the last four quarters.

What is COLL's EPS?

Diluted earnings per share over the last four quarters were $1.24; −$0.46 in the latest quarter.

COLL ownership and insider trades · All stocks